Plain-English translation of NCT06526208 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers are testing a medication called (a cannabis-based oil with a 23:1 ratio of CBD to THC) to see if it can safely and effectively reduce anxiety in autistic adults. The study involves 108 participants who will either receive the active medication or a placebo oil, taken by mouth daily over 8 weeks. This is an early-stage trial designed to understand how safe and helpful this treatment might be.
Many autistic adults experience significant anxiety that can affect their daily lives, but current treatments don't work well for everyone. Researchers want to explore whether this medication could be a new option for people with autism who struggle with anxiety.
You likely qualify if…
You likely don't qualify if…
You'll start with a 3-week screening period where the study team confirms your autism diagnosis and checks your overall health. Then you'll enter the active 8-week phase, during which you'll take either the medication or placebo oil by mouth once or twice daily—the dose gradually increases over the first 4 weeks, then stays at the highest level for weeks 5–8. You'll visit the clinic regularly, keep a dosing diary, have your study partner complete behavioral assessments, and return for one final check-up two weeks after the treatment ends.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States